Open access
Oct 2026
Engineered receptor-biased IL-2-drug immunoconjugates selectively expand Tregs and suppress effector cells for autoimmune therapy.
Autoimmune and inflammatory diseases arise from a breakdown of immune tolerance driven by hyperactivation of effector lymphocytes and dysfunction of regulatory T (Treg) cells. Interleukin-2 (IL-2) supports both Treg maintenance and effector cell responses, necessitating careful dose optimization for selective immune re...
Jing Li, Shan-Bo Yang, Ye-Shuang Yuan et al.
· Cell Reports Medicine · 0 citations